Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen Jaeger

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Cancers|May 25, 2024
Frequency of Common and Uncommon <i>BRAF</i> Alterations among Colorectal and Non-Colorectal Gastrointestinal MalignanciesAmit Mahipal, Michael H Storandt, Emily A Teslow, et al.
Clinical Lung Cancer|March 10, 2025
Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung CancersRadhika Gutta, Emily Teslow, Ellen Jaeger, et al.
NPJ Precision Oncology|July 4, 2025
Genetic and oncogenic features of RASGRF fusionsSreya Das, Daniel S Lenchner, Ellen Jaeger, et al.
International Journal of Molecular Sciences|July 28, 2022
3D Printed Solutions for Spheroid Engineering and Cancer ResearchTobias Butelmann, Yawei Gu, Aijun Li, et al.
The Oncologist|October 9, 2022
Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus AvelumabCharlotte Manogue Hawkins, Pedro C Barata, Patrick Cotogno, et al.
Cancers|May 14, 2025
Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated CancersCatherine H Marshall, Ali T Arafa, Ellen Jaeger, et al.
The Prostate|March 24, 2021
Family history and pathogenic/likely pathogenic germline variants in prostate cancer patientsRachel A Sabol, Elisa M Ledet, Ellen Jaeger, et al.
Frontiers in Oncology|November 16, 2020
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional CohortPedro Barata, Whitley Hatton, Arpita Desai, et al.
Journal for Immunotherapy of Cancer|August 14, 2020
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNAPedro Barata, Neeraj Agarwal, Roberto Nussenzveig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2025
ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast CancerChang-Ching A Lin, María Rosario Chica-Parrado, Nisha Unni, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Cancers|May 25, 2024
Frequency of Common and Uncommon <i>BRAF</i> Alterations among Colorectal and Non-Colorectal Gastrointestinal MalignanciesAmit Mahipal, Michael H Storandt, Emily A Teslow, et al.
Clinical Lung Cancer|March 10, 2025
Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung CancersRadhika Gutta, Emily Teslow, Ellen Jaeger, et al.
NPJ Precision Oncology|July 4, 2025
Genetic and oncogenic features of RASGRF fusionsSreya Das, Daniel S Lenchner, Ellen Jaeger, et al.
International Journal of Molecular Sciences|July 28, 2022
3D Printed Solutions for Spheroid Engineering and Cancer ResearchTobias Butelmann, Yawei Gu, Aijun Li, et al.
The Oncologist|October 9, 2022
Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus AvelumabCharlotte Manogue Hawkins, Pedro C Barata, Patrick Cotogno, et al.
Cancers|May 14, 2025
Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated CancersCatherine H Marshall, Ali T Arafa, Ellen Jaeger, et al.
The Prostate|March 24, 2021
Family history and pathogenic/likely pathogenic germline variants in prostate cancer patientsRachel A Sabol, Elisa M Ledet, Ellen Jaeger, et al.
Frontiers in Oncology|November 16, 2020
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional CohortPedro Barata, Whitley Hatton, Arpita Desai, et al.
Journal for Immunotherapy of Cancer|August 14, 2020
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNAPedro Barata, Neeraj Agarwal, Roberto Nussenzveig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2025
ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast CancerChang-Ching A Lin, María Rosario Chica-Parrado, Nisha Unni, et al.
Pageof 2